GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » 3-Year EPS without NRI Growth Rate

InVivo Therapeutics Holdings (FRA:04I) 3-Year EPS without NRI Growth Rate : 79.80% (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings 3-Year EPS without NRI Growth Rate?

InVivo Therapeutics Holdings's EPS without NRI for the three months ended in Sep. 2023 was €-0.82.

During the past 3 years, the average EPS without NRI Growth Rate was 79.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 80.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of InVivo Therapeutics Holdings was 86.70% per year. The lowest was -746.70% per year. And the median was 29.50% per year.


Competitive Comparison of InVivo Therapeutics Holdings's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, InVivo Therapeutics Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's 3-Year EPS without NRI Growth Rate falls into.



InVivo Therapeutics Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


InVivo Therapeutics Holdings  (FRA:04I) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


InVivo Therapeutics Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (FRA:04I) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines